testing the effect of a DPP-4 inhibitor on immune function

在过去的一年里，我们已经获得了IRB对这一临床方案的最终批准，即评估DPP-4特异性抑制剂(Sitagliptin/Januvia)对健康个体免疫功能的影响。今年1月，协议号09DK-0055被分配。第一个参与者是在4月份注册的。到2009财年结束时，共招募了8名志愿者，3名志愿者完成了研究。另有7人完成了调查问卷，经审查符合纳入/排除研究的标准。这些人将被安排在今年秋天进行筛查访问/潜在注册。研究性研究分析正在进行中。到目前为止，对于所有的研究访问，都对PBMC进行了流式细胞术分析。一旦每个志愿者完成了所有6次研究访问，就会进行其他免疫测试。

In the past year, we have obtained final IRB approval for this clinical protocol, Assessment of the Effects of A DPP-4-Specific Inhibitor (Sitagliptin/Januvia) On Immune Function In Healthy Individuals. In January, the protocol number, 09DK-0055, was assigned. The first participant was enrolled in April. By the end of FY09, a total of 8 volunteers will have been enrolled, and 3 volunteers will have finished the study. An additional 7 individuals have completed questionnaires that have been reviewed to fit within the study inclusion/ exclusion criteria. These individuals will be scheduled for screening visits/ potential enrollment this fall. The research study assays are ongoing. For all study visits to date, flow cytometry assays have been performed on PBMCs. Other immune assays are being done once each volunteer has completed all 6 study visits.